• BUSINESS WIRE )--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. (businesswire.com)
  • The improvement in progression-free survival observed with datopotamab deruxtecan, particularly in patients with non-squamous tumors, and the improved tolerability of this antibody drug conjugate compared to docetaxel, represent a meaningful advance for patients with lung cancer. (businesswire.com)
  • Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1-positive advanced non-small cell lung cancer. (curetoday.com)
  • Keytruda (pembrolizumab) continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1-positive advanced non-small cell lung cancer (NSCLC) after more than five years of follow-up, according to results from the phase 2/3 KEYNOTE-010 study presented at the 2020 World Conference on Lung Cancer. (curetoday.com)
  • In the KEYNOTE-010 trial, treatment with Keytruda significantly improved overall survival (the period of time patients on a trial are still alive after they are diagnosed or started treatment) and progression-free survival (the time from treatment to disease progression or worsening). (curetoday.com)
  • In the five-year follow-up, the agent continued to significantly improve overall and progression-free survival, compared with docetaxel, in patients with a PD-L1 Tumor Proportion Score (TPS) of 50% or greater and a PD-L1 TPS of 1% or greater. (curetoday.com)
  • In the follow-up analysis, the study authors aimed to evaluate long-term overall and progression-free survival. (curetoday.com)
  • Median progression-free survival rates were also superior for those with a PD-L1 TPS of 50% or greater (5.3 months versus 4.2 months) and 1% or greater (4 months versus 4.1 months). (curetoday.com)
  • We continue to see a clinically meaningful improvement in (overall survival) and (progression-free survival). (curetoday.com)
  • A retrospective analysis 4 of 323 patients with advanced oropharyngeal squamous cell cancer enrolled in a randomized clinical trial found a 3-year overall survival rate of 82.4% for HPV-associated disease vs 57.1% for HPV-negative disease, and progression-free survival of 73.7% vs 43.4%, Dr. Agrawal reported. (ascopost.com)
  • The median progression-free survival was 7.7 months in the control arm and 12.6 months in the HIPEC arm (P = 0.020). (lu.se)
  • The ALFA decision tool is a simple, robust, and discriminant prognostic model for AML patients ≥60 years of age treated with intensive chemotherapy. (nih.gov)
  • New Phase III trial data suggests giving colon cancer patients Roche's oral anticancer drug Xeloda in combination with intravenous oxaliplatin immediately after surgery boosts disease-free survival compared with combined postsurgery chemotherapy using 5-fluorouracil/leucovorin. (genengnews.com)
  • Years ago, we saw results of some small, single-arm phase 2 studies, suggesting that some of those patients may be so sensitive to biologic therapy that they have a pathologic complete response with HER2-targeted therapy - HER2-targeted therapy with endocrine therapy if they are positive - with no chemotherapy at all. (medscape.com)
  • If they still had residual disease, they got chemotherapy if chemotherapy had not been administered before, and they may have gotten other HER2-targeted therapies if they had already received chemotherapy. (medscape.com)
  • However, the identification of factors predicting a worse survival in stage II colon cancer led the American Society of Clinical Oncology (ASCO) [ 3 - 5 ], the Nationonal Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) to define a collective of high-risk patients who may benefit from adjuvant chemotherapy. (biomedcentral.com)
  • The TROPION-Lung01 results demonstrate for the first time that an antibody drug conjugate can delay disease progression or death for longer than conventional chemotherapy in patients with advanced non-small cell lung cancer. (businesswire.com)
  • A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. (scienceblog.com)
  • While previous research has evaluated the use of various forms of "dose dense" chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer. (scienceblog.com)
  • With the availability of new drugs to control one of the most serious side effects of chemotherapy administration, we can further increase the chances of survival for women with breast cancer. (scienceblog.com)
  • In addition to improved disease-free survival, the study indicated that dose dense chemotherapy may also lead to higher overall survival rates. (scienceblog.com)
  • When R0/R1 surgery is achieved, patients receive S-1 chemotherapy for 1-year post-operatively. (nih.gov)
  • A team of medical researchers in Italy have achieved what they are calling "excellent" tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. (survivingmesothelioma.com)
  • From then on I decided not to operate on patients immediately if they were tumor-free after radiation and chemotherapy. (fapesp.br)
  • After the first year without tumor regrowth, the chances of recurrence are virtually the same regardless of the dose of radiation and chemotherapy or the tumor stage on initial diagnosis," explains the surgeon. (fapesp.br)
  • For advanced disease, prognostic factors may provide information for those wishing to use treatment other than the ABVD regimen (Table 1) or other standard chemotherapy regimens. (cancernetwork.com)
  • as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
  • Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
  • Chemotherapy is an option is the disease has spread beyond its origin, or if it has proven refractory on antibiotics. (lymphomainfo.net)
  • The records of eligible patients using surgery, chemotherapy, registered during a 2-month period A data col ection form (Annex 1) was radiotherapy, hormone thera- of each year, starting from 2008 and designed to reconstruct the trajecto- py, and targeted therapy at the ending in 2017, were scanned for in- ry of patients in the health-care sys- two oncology centres and any formation. (who.int)
  • The aim of this study was to evaluate the relationship between the monocyte count assessed at diagnosis and disease-free survival and prognosis in patients with esophageal cancer. (researchsquare.com)
  • Significant parameters used in the determination of the prognosis and survival of esophageal cancer include tumor stage, surgical margin, and metastatic lymph node status. (researchsquare.com)
  • In the past, transla- progesterone receptor (PgR) expression, and all of the tional research focused on single biological markers following features: pT 6 2 cm, grade I, age P 35 years which could putatively discriminate patients' prognosis should be considered in this low-risk category, whereas or treatment response. (lu.se)
  • While localized melanoma has an excellent prognosis, regional and distant disease is associated with much poorer outcomes. (medscape.com)
  • Early diagnosis affords a better chance of survival and better prognosis [3]. (who.int)
  • SAN ANTONIO - Data from the NRG (NSABP B-39/RTOG 0413) trial indicated that ipsilateral breast tumor recurrence (IBTR) rates 10 years after treatment could not reject the hypothesis that accelerated partial breast irradiation (PBI) after lumpectomy was inferior to whole breast irradiation (WBI), according to a presentation at the 2018 San Antonio Breast Cancer Symposium , held Dec. 4-8. (aacr.org)
  • 1 percent) and RFI (1.5 percent) between the two treatment arms at 10 years, we could not declare that WBI and PBI were equivalent in controlling local in-breast tumor recurrence because the hazard ratio between arms fell short of meeting statistical equivalence," said Vicini. (aacr.org)
  • Background: This study aimed to determine the relationship between the pre-operative metabolic tumor volume (MTV) and the disease-free survival (DFS) of patients with stage I non-small cell lung cancer (NSCLC) using F-18 2-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography-computed tomography (PET-CT) scanning. (iiarjournals.org)
  • Although younger children and children with invasive tumor types generally experience less favorable outcomes, total removal of the tumors is the most conspicuous prognostic factor for both survival and relapse. (wikipedia.org)
  • Expression of two additional candidate genes, S100A6 and S100A4 on chromosome 1q have also been found to correspond to supratentorial tumor development and tumors occurring before the age of 3 years old, though it is unclear exactly what role these genes play in the etiology. (wikipedia.org)
  • An evolving paradigm expanding the genetic basis of cancer suggests that developmental programs indelibly imprint restricted repertoires of homeostasis, forming the substrate for lineage-dependent tumor induction by deregulation of tissue-specific survival pathways. (jefferson.edu)
  • When she told her patient the news that she was cured, Habr-Gama was asked in reply: "If I was tumor-free, why did you operate on me in the first place? (fapesp.br)
  • The results suggest that those patients who were recurrence-free three years after diagnosis had less than a 5% risk of tumor regrowth and only a 2% risk of metastasis. (fapesp.br)
  • The most notable finding in the paper is in its analysis of conditional survival, or the chances of a patient remaining disease-free after each year without tumor regrowth. (fapesp.br)
  • However, our research found that after a person has been tumor-free for three years, the risk of relapse becomes negligible," says lead study author Rodrigo Oliva Perez, who also works at the Angelita and Joaquim Gama Institute. (fapesp.br)
  • In showing that the risk of tumor recurrence drops dramatically after three years, the article supports the idea that, after this period has passed, patient follow-up with imaging and consultations can be less intense. (fapesp.br)
  • Although it is unclear exactly how loss of BAP1 function leads to BAP1 tumor predisposition syndrome, researchers speculate that altered activity of proteins normally regulated by BAP1 deubiquitination may promote cell proliferation or survival, resulting in tumor formation. (medlineplus.gov)
  • Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
  • Previously, Slamon and researchers at the Jonsson Cancer Center demonstrated that adding ribociclib, a cyclin-dependent kinase inhibitor, to the standard hormone therapy improves overall survival in both premenopausal and postmenopausal women with metastatic HR positive/HER2 negative breast cancer. (nepalnews.com)
  • Drug-eluting beads trans-arterial chemoembolization for leiomyosarcoma, liver metastases from colorectal cancer, and for primary and liver-dominant metastatic disease of the liver. (aetna.com)
  • The 15-year survival rate is 12.5% for a person with an invasive thymoma and 47% for a person with a noninvasive thymoma. (medscape.com)
  • A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment. (nepalnews.com)
  • Researchers from UCLA Jonsson Comprehensive Cancer Centre found that individuals who received the combination therapy had much longer invasive disease-free life than those who received hormone therapy alone, regardless of whether the cancer had progressed to the lymph nodes. (nepalnews.com)
  • Invasive disease-free survival was the primary endpoint of the study. (nepalnews.com)
  • Invasive disease-free survival was evaluated after 426 events. (nepalnews.com)
  • At the time of this analysis, 189 people in the ribociclib group experienced an invasive disease-free survival event, compared to 237 people in the hormone therapy alone group. (nepalnews.com)
  • The data showed a statistically significant improvement in the risk of invasive disease in favour of the combination arm. (nepalnews.com)
  • The invasive disease-free survival rates at three years were 90.4%, compared to 87.1% for women who were treated with only hormone therapy. (nepalnews.com)
  • The trial found that people taking abemaciclib had a higher invasive disease-free survival rate , meaning they were less likely to have breast cancer come back in the time studied. (lbbc.org)
  • Looking specifically at people in the study who had Ki-67 scores of 20 percent or higher, the researchers found an even larger difference in 2 year invasive disease-free survival rates. (lbbc.org)
  • We retrospectively reviewed the clinicopathological characteristics and survival outcomes. (sages.org)
  • Patients with duodenal GIST who underwent complete surgical resection have favorable survival outcomes. (sages.org)
  • AIM: To evaluate the clinical outcomes of laparoscopic resection of colorectal cancer in patients over 80 years old. (sages.org)
  • Our hope is that these results, along with our commitment to long-term research of Tecartus, will continue to provide clarity to physicians on optimal treatment methods for these patients living with this rare disease who have suffered historically poor outcomes. (gilead.com)
  • In addition, with 1.7 years of follow up, outcomes are encouraging with high estimated 3-year DFS and OS. (clevelandclinic.org)
  • NATIONAL HARBOR, Md. -- The aromatase inhibitor anastrozole (Arimidex) extended its disease control advantage over tamoxifen in an analysis of 10-year outcomes in a large randomized clinical trial in breast cancer. (medpagetoday.com)
  • Explain to interested patients that the aromatase inhibitor anastrozole (Arimidex) extended its disease control advantage over tamoxifen in an analysis of 10-year outcomes in a large randomized clinical trial in breast cancer. (medpagetoday.com)
  • Reproductive and obstetrical outcomes with the overall survival of fertile-age women treated with fertility-sparing surgery for borderline ovarian tumors in Sweden: a prospective nationwide population-based study. (cancercentrum.se)
  • Primary outcome measures include 30-days mortality, overall and disease-free survival. (sages.org)
  • RESULTS: There is no statistical significant difference in 30-days mortality, overall and disease-free survival between 2 groups. (sages.org)
  • The primary endpoints were disease-free survival, recurrence or a new primary cancer, all-cause mortality, and safety/tolerability. (medpagetoday.com)
  • Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil. (oncolink.org)
  • Breast cancer is one of the world's leading causes of mortality in women 35 years of age or more [1]. (who.int)
  • Most of the analyzed patients were hospitalized with a moderate form of disease, explaining the significant percentage of 25% mortality. (cdc.gov)
  • BACKGROUND: Although disease-free survival (DFS) is accepted as a valid end point in adjuvant breast cancer trials, improvement in 2-year DFS has never been formally established as an adequate correlate for 5-year overall survival (OS). (mcmaster.ca)
  • DESIGN: We conducted a systematic Medline search (1966-2006) for randomized adjuvant breast cancer trials of >100 patients per arm with 2-year DFS and 5-year OS data. (mcmaster.ca)
  • Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase III study. (ascopost.com)
  • In the adjuvant trial, they used 400 mg, and that was intentional to try to reduce some of the toxicity because the plan was for 3 years of therapy. (medscape.com)
  • Adjuvant treatment is usually reserved to stage III disease. (biomedcentral.com)
  • In this planned final analysis of overall survival from the phase 3 ADAURA trial, adjuvant osimertinib resulted in significantly longer overall survival than placebo among patients with completely resected, EGFR-mutated, stage II to IIIA NSCLC as well as in the overall population (patients with stage IB to IIIA disease). (cdc.gov)
  • Hodgkin's lymphoma (HL) is a rare, curable malignancy, and investigators have made remarkable improvements in treatment of the disease over the past 20 years. (cancernetwork.com)
  • The Capizzi regimen, which involves the administration of escalating-dose methotrexate and L-asparaginase, has been the standard treatment for ALL for the past 20 years. (medscape.com)
  • Nandivada P, Tirabassi M. Invited Commentary: Persistence Pays Off- Pursuing NED Status in Hepatoblastoma Improves Survival: An Observational Study by Fleming A, et?al. (umassmed.edu)
  • In the follow-up, treatment with Keytruda continued for 35 cycles, or approximately two years, or until disease progression or unacceptable toxicity. (curetoday.com)
  • According to Sandeep Samant, MD , Chief of Head and Neck Surgery at Northwestern Medicine and symposium Chair, "The goal of deintensification is to reduce late toxicity, while maintaining high survival and normal functioning related to swallowing, saliva, and taste. (ascopost.com)
  • The goal of deintensification is to reduce late toxicity, while maintaining high survival and normal functioning related to swallowing, saliva, and taste. (ascopost.com)
  • CONCLUSIONS: This technique, although time-consuming, achieves good local disease control with a satisfactory toxicity profile in both early-stage and local recurrent breast cancer patients. (bvsalud.org)
  • Secondary endpoints included RFI, distant disease-free interval (DDFI), and overall survival (OS). (aacr.org)
  • Duration of remission and relapse-free survival, overall survival, minimal residual disease (MRD) negativity rate, and alloSCT rate were assessed as secondary endpoints. (gilead.com)
  • The primary outcome of the STEM-PD trial is to assess safety and tolerability of the transplanted product at 1-year post-transplantation, while secondary endpoints will assess survival and function of the transplanted cells by brain imaging, as well as measure effects on Parkinson's symptoms. (lu.se)
  • A study conducted by the Memorial Sloan-Kettering Cancer Center reported 5-year and 10-year survival rates for various stages of thymomas (see Table 1 below). (medscape.com)
  • It's been an exciting year for breast cancer news. (medscape.com)
  • Of course, the risk of second malignancy is also a risk in adults, but the fact that the median age of adult cancer patients at diagnosis is in the seventh decade, that second malignancies after radiotherapy are uncommon in adults, and that they usually manifest 10-15 years after treatment make them less of a concern. (nature.com)
  • Because of advancements in screening and public awareness, the majority of breast cancer patients in the U.S. are diagnosed in early stages, and over 100,000 women each year face treatment decisions about breast-conserving therapy," said Frank Vicini, MD , principal investigator at the MHP Radiation Oncology Institute/21st Century Oncology in Pontiac, Michigan. (aacr.org)
  • Our findings showed that monocyte count is a prognostic factor affecting disease-free survival in patients with esophageal cancer, regardless of histological subtype. (researchsquare.com)
  • In the present study, we aimed to investigate whether the monocyte count measured at the time of diagnosis can be used as a new prognostic biomarker in predicting disease-free survival in patients with esophageal cancer. (researchsquare.com)
  • To put this study in context, the first child who received CAR T-cell therapy for B-ALL after multiple relapses has recently celebrated her 10-year cancer-free survival milestone, and we hope that our finding will result in many more such milestones. (cancer.net)
  • This study provides compelling evidence that ITC in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival. (biomedcentral.com)
  • If confirmed and extended by additional research, this finding could positively affect the care of thousands of patients throughout the world with breast cancer and perhaps, eventually, other diseases. (scienceblog.com)
  • People with colon cancer often experience bowel movement changes, but no single stool shape indicates this disease. (medicalnewstoday.com)
  • The symptoms of colon cancer depend on the individual and the disease stage. (medicalnewstoday.com)
  • Colon cancer staging indicates how much the disease has grown and spread. (medicalnewstoday.com)
  • About 90% of people who receive an early diagnosis of colon cancer will survive for at least 5 years. (medicalnewstoday.com)
  • The overall 5-year survival rate for colon cancer is 64% for all stages combined. (medicalnewstoday.com)
  • The risk of cancer returning decreases significantly after an individual has been symptom-free for 5 years. (medicalnewstoday.com)
  • According to cancer statistics for 2015, 60,300 individuals were diagnosed with PRAD and 26,600 patients succumbed to the disease in China. (spandidos-publications.com)
  • All elective resection of colorectal cancer in patients over 80 years old were included. (sages.org)
  • Hormonal treatment of advanced prostate cancer should be consideredfor patients who have stages C and D1 disease, a high risk of recurrenceafter local therapy, or prostate-specific antigen-measured recurrenceafter local treatment. (cancernetwork.com)
  • The rectum remaining cancer-free is the best predictor of a reduced risk of recurrence. (fapesp.br)
  • Non-communicable diseases, including breast cancer (BC), in Africa have been gaining more attention recently since improvements are seen in the management against infectious diseases, poor maternal health, and malnutrition. (karger.com)
  • More than 20% of these deaths from non-communicable diseases are cancer-related deaths [ 1 ]. (karger.com)
  • These patients have a long life expectancy-you can expect them to live 30 to 50 years or even longer as life expectancy continues to increase-vs head and neck cancer patients with disease related to smoking, who are diagnosed in their 60s and have maybe another 10 to 20 years to live because of other smoking-related cancers and medical comorbidities. (ascopost.com)
  • AALL0232 was a phase 3 randomized trial for patients 1 to 30 years of age with newly diagnosed National Cancer Institute high-risk B-precursor ALL that evaluated the safety and efficacy of interventions targeted to enhance CNS control. (medscape.com)
  • A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center . (mdanderson.org)
  • HR-positive/HER2-negative breast cancer is the most common subtype of the disease and accounts for nearly 70% of breast cancer cases in the Unites States. (nepalnews.com)
  • At 10 years of median follow-up, anastrozole is significantly superior to tamoxifen in preventing breast cancer recurrence," said Buzdar. (medpagetoday.com)
  • A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology. (medicaldaily.com)
  • Factors associated with survival in pediatric adrenocortical carcinoma: An analysis of the National Cancer Data Base (NCDB). (oncolink.org)
  • Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. (oncolink.org)
  • Reda Wilson has worked in cancer prevention and control more than 30 years, including 18 years at the Centers for Disease Control and Prevention's (CDC) Division of Cancer Prevention and Control. (cdc.gov)
  • More than 30 years ago, a mother who had been treated for cancer ended up dying from it and left her family in financial ruin. (cdc.gov)
  • During my years at ASCR, I performed cancer studies, gave presentations to communities about cancer in their area, appeared regularly on a local television program, and was even interviewed by a well-respected national news magazine. (cdc.gov)
  • After 10 years at ASCR, I joined CDC in the Division of Cancer Prevention and Control, Cancer Surveillance Branch as a program consultant. (cdc.gov)
  • I hope that over the next 30 years, NPCR and CDC increase our cancer surveillance, expand prevention resources, and continue to push toward a future free of cancer. (cdc.gov)
  • I'm pleased when I see reports showing decreasing cancer rates and improved survival. (cdc.gov)
  • Three-year OS and DFS in the recurrent and primary cancer groups were 87% vs. 89%, and 96 % vs. 97.8%, respectively. (bvsalud.org)
  • A study conducted by the Memorial Sloan-Kettering Cancer Center reported 5-year and 10-year survival rates to corresponding stages of thymomas (see Table 1 below). (medscape.com)
  • 1. Dahm-Kähler P, Palmqvist C, Staf C, Holmberg E, Johannesson L. Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study. (cancercentrum.se)
  • Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a SweGCG study. (cancercentrum.se)
  • Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer - a Swedish Gynecologic Cancer Group (SweGCG) study. (cancercentrum.se)
  • No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study. (cancercentrum.se)
  • Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment. (cancercentrum.se)
  • Indeed, while the risks of breast, ovarian, pancreatic and prostate cancer have been documented for years, recent data show an increased risk of gastric cancer, and suggest an association with lung cancer. (cdc.gov)
  • The PRS was evaluated for association with lung cancer risk adjusting for age, sex, total pack-years, family history of lung cancer, history of COPD, and the top five principal components for genetic ancestry. (cdc.gov)
  • The study was conducted using DNA from 133 heavy smokers who had not developed lung cancer at a mean age of 80 years, and from another 116 heavy smokers who had developed this type of cancer at a mean age of 50 years. (cdc.gov)
  • The primary analysis showed no significant differences in disease-free survival, with a median duration of 5.8 years (interquartile range [IQR] = 1.6-8.2 years) for sunitinib (hazard ratio [HR] = 1.02, P = .8038, vs placebo), 6.1 years (IQR = 1.7 years to not estimable) for sorafenib (HR = 0.97, P = .7184, vs placebo), and 6.6 years (IQR = 1.5 years to not estimable) for placebo. (ascopost.com)
  • The presence of ITC was associated with a significantly worse disease-free survival (hazard ratio = 4.73, p = 0.005). (biomedcentral.com)
  • Similarly, ITC were associated with significantly worse overall survival (hazard ratio = 3.50, p = 0.043). (biomedcentral.com)
  • The 10-year report showed a recurrence rate of 19.7% with anastrozole and 24% with tamoxifen, a difference that translated into a hazard ratio of 0.79 in favor of anastrozole ( P =0.0002). (medpagetoday.com)
  • Anastrozole also was associated with a 14% reduction in the hazard ratio for disease-free survival ( P =0.003). (medpagetoday.com)
  • l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope? (thalassaemia.org.cy)
  • This review describes current considerations in the use of hydroxyurea for the management of sickle cell disease in the context of clinical severity. (cdc.gov)
  • Dr. Keith Hoots, the Division Director at the Division of Blood Diseases and Resources (DBDR) opened the meeting by greeting the Sickle Cell Disease Advisory committee (SCDAC) members. (nih.gov)
  • In 1999 there were 2 major obstacles for curing adults with sickle cell disease. (nih.gov)
  • Moreover, gain of chromosome 1q25 has been found to independent prognostic value for recurrence-free and overall survival. (wikipedia.org)
  • Moreover, the 10-year estimates for relapse-free interval (RFI) disclosed a statistically significant inferiority for PBI compared to WBI. (aacr.org)
  • Median (95% CI) relapse-free survival (RFS) censored and not censored at subsequent alloSCT were both 11.6 (2.7-20.5) and 11.7 months (2.8-20.5), respectively. (gilead.com)
  • The researchers found that two dose dense regimens provided significantly higher disease-free survival rates than two regimens using conventional dosing, and that efficacy did not differ between the two dose dense regimens. (scienceblog.com)
  • Purpose: To record failure rates and identify the contributing factors to implant failure and marginal bone loss (MBL) of implants placed and rehabilitated by inexperienced post-graduate students at the one-year follow-up. (mdpi.com)
  • The new mesothelioma study, conducted at several US medical centers and published in the Annals of Thoracic Surgery, analyzed the survival rates of 73 patients diagnosed with the epithelioid form of pleural mesothelioma between 2005 and 2013. (survivingmesothelioma.com)
  • With every year without recurrence, survival rates improve. (fapesp.br)
  • Although the remission rates with this approach have been high, the median disease-free survival (DFS) has been short. (clevelandclinic.org)
  • The type of therapy given to these patients determines long-term survival rates. (cancernetwork.com)
  • There is just no clarity on how that treatment needs to change safely without giving up on survival rates," Dr. Samant said. (ascopost.com)
  • As a result of the rapid advances in genetics technology and the Human Genome Project, most of the estimated 100,000 genes in humans will be identified by the year 2005 (1). (cdc.gov)
  • While these figures are lower than those for the US, the incidence of PRAD is rapidly increasing each year in China ( 6 ). (spandidos-publications.com)
  • Deforestation in northeastern Thailand early in the last century led to an extreme reduction in the incidence of malaria ( 5 ) because the main vector mosquito in this area, Anopheles dirus sensu stricto, is forest dwelling and requires a shaded environment for its survival and reproduction ( 6 ). (cdc.gov)
  • new plantations lead to increased mosquito density and disease incidence ( 8 ). (cdc.gov)
  • The incidence is highest among women ages 65 to 74 years. (msdmanuals.com)
  • Melanoma is a global health problem and the incidence of this disease is rising. (medscape.com)
  • Results: During a median follow-up duration of 24 months, two patients died of disease progression, and 11 experienced recurrent tumors (eight intrathoracic tumors, two distant metastasis, and one both types of recurrences). (iiarjournals.org)
  • It has been said that African patients present late with aggressive tumors and face a lack of therapeutic options, resulting in short survival duration. (karger.com)
  • The median duration on study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20% and 57% patients respectively. (nepalnews.com)
  • Association of the initial RT-PCR Ct values with disease duration was assessed by adjusted linear regression approach. (bvsalud.org)
  • A univariate regression model weighted by trial sample size was constructed to determine whether 2-year DFS differences between treatment arms within trials were predictive of 5-year OS differences. (mcmaster.ca)
  • CONCLUSION: There is a statistically significant correlation, of moderate strength, between difference in 2-year DFS between treatment comparisons and difference in 5-year OS but the correlation is not strong enough to be used as a predictor. (mcmaster.ca)
  • Because of the well-documented propensity for late recurrences, long-term survival should be considered in terms of a 10-year follow-up after treatment of the thymoma. (medscape.com)
  • The proportion of patients IBTR-free 10 years after treatment was 95.2 percent among those who received PBI and 95.9 percent among those who received WBI. (aacr.org)
  • The difference in the 10-year RFI between the two treatment arms was statistically significant (91.9 percent for patients treated with PBI versus 93.4 percent for patients treated with WBI). (aacr.org)
  • Period after successful treatment in which there is no appearance of the symptoms or effects of the disease. (umassmed.edu)
  • The effect of monocyte count assessed in the blood samples taken at the time of diagnosis prior to the initiation of the treatment on disease-free survival was investigated. (researchsquare.com)
  • In an article published in the Journal of Clinical Oncology , the study authors reported that 99% of the 194 patients in the clinical trial had undetectable disease after the treatment. (cancer.net)
  • When the treatment began, 70% of the participants were younger than 10 years old. (cancer.net)
  • The predomination of an androgen-independent phenotype canoccur approximately 1 to 2 years afterthe initiation of androgen deprivation.Multiple strategies have been usedto induce serum levels of testosteronesimilar to those following castration.Traditional treatment options for androgenblockade include orchiectomy,luteinizing hormone-releasing hormone(LHRH) agonists and antagonists,nonsteroidal antiandrogens, andestrogens. (cancernetwork.com)
  • Habr-Gama had already suspected that every year under the watch-and-wait strategy meant a better response to treatment. (fapesp.br)
  • In addition, patients who received Keytruda for six months or more could also receive a second course with the drug for up to one year after their disease progressed when they stopped their initial treatment. (curetoday.com)
  • Lastly, 21 patients received a second course of Keytruda after their disease progressed following the first round of treatment. (curetoday.com)
  • Hydroxyurea has proven clinical efficacy for SCA - treatment significantly reduces disease manifestations and prolongs survival. (cdc.gov)
  • Despite significant improvements in the treatment of Hodgkin's lymphoma over the past 2 decades, physicians continue to face dilemmas in therapy for the disease, and many cured patients live with complications of treatment. (cancernetwork.com)
  • Newer therapeutic options are still needed for the disease, to minimize complications and to improve the treatment of patients in relapse. (cancernetwork.com)
  • This review considers the treatment of Hodgkin's lymphoma in younger patients, addressing such issues as which patients with early-stage disease may require radiotherapy, what prognostic factors provide information that can affect treatment choices in patients with advanced disease, and what we have learned about treatment complications in this setting. (cancernetwork.com)
  • Still, physicians face dilemmas in therapy for the disease, and many cured patients live with complications of treatment. (cancernetwork.com)
  • In this review, we consider the treatment of HL in younger patients, first evaluating recent clinical trials for early-stage disease, with a special focus on which patients may still need radiotherapy (RT). (cancernetwork.com)
  • Recent trials suggest that ABVD or variants of this combination with or without RT may still be the best therapy for early-stage HL, regardless of the type of disease presentation, and the potential for complications of therapy may ultimately direct choices of treatment. (cancernetwork.com)
  • Although event-free survival continues to improve for children and young adults with high-risk ALL, CNS disease has become an increasing site of treatment failure, the authors note. (medscape.com)
  • This report offers an additional two years of follow-up data and statistics on bone marrow undetectable measurable residual disease (U-MRD) after treatment. (mdanderson.org)
  • But with the PENELOPE-B trial, also presented Wednesday, and the PALLAS trial, which came out earlier this year, showing no benefit to adding a CDK 4/6 inhibitor in a similar context, some doctors are cautioning that longer follow-up may be needed before changing current treatment plans. (lbbc.org)
  • Consistent with previous reports from the study, survival did not differ significantly between treatment groups. (medpagetoday.com)
  • After randomization, four patients in the HIPEC arm and six in the control arm were not treated using the intended therapy, one patient because of withdrawal, one because of a life-threatening other malignant disease and the others because of progressive disease before initiation of the treatment. (lu.se)
  • During the follow-up, one patient was crossed over from the control arm and underwent cytoreduction and HIPEC for recurrent disease, after the assigned treatment was completed. (lu.se)
  • and gy centre for the years and months treatment (surgery, radiotherapy, · to document the quality and shown in Table 2.1. (who.int)
  • An investigational stem cell-based therapy for the treatment of Parkinson's Disease, STEM-PD, has been given regulatory approval for a Phase I/IIa clinical trial. (lu.se)
  • Unfortunately, up to 20 % of stage I & II disease patients will develop recurrence within five years after diagnosis. (biomedcentral.com)
  • This is called event-free survival. (cancer.net)
  • Among these patients, the 12-month event-free survival was 85%, compared to about 69% among the 116 participants who did not receive a stem cell transplant. (cancer.net)
  • In a planned interim analysis, 5-year event-free survival for patients who received the high-dose regimen was 82%, compared with 75% for those receiving the escalation protocol. (medscape.com)
  • In another paper, the cumulative survival in 150 adults was followed from 2003 to 2016 and patients were screened for heart, lung, and kidney disease. (nih.gov)
  • The 3-year disease-free survival results look very reassuring. (medscape.com)
  • Results from a recent study from China showed that a new approach to chimeric antigen receptor (CAR) T-cell therapy was able to put B-cell acute lymphoblastic leukemia (ALL) into remission in many children with high-risk disease. (cancer.net)
  • SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ® (brexucabtagene autoleucel). (gilead.com)
  • Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analysis. (gilead.com)
  • MD Anderson researchers previously reported results from this study showing that ibrutinib and venetoclax were effective when given together for high-risk and older patients with the disease. (mdanderson.org)
  • These long-term results show that two years of oral targeted therapy can achieve lasting disease remission for patients with CLL. (mdanderson.org)
  • This trial has now been updated to a minimal follow-up of 6 years to show long-term results. (lu.se)
  • Results: At the time of this update, the median follow-up was almost 8 years (range 72-115 months). (lu.se)
  • Results of a 20-year single center retrospective analysis. (medscape.com)
  • Children with certain hereditary diseases, such as neurofibromatosis type II (NF2), have been found to be more frequently afflicted with this class of tumors, but a firm genetic link remains to be established. (wikipedia.org)
  • These node-negative patients experienced longer survival even though their mesothelioma tumors began growing again a median of 2.4 years after surgery. (survivingmesothelioma.com)
  • Adrenocortical tumors encompass a spectrum of diseases with often seamless transition from benign (adenoma) to malignant (carcinoma) behavior. (oncolink.org)
  • Childhood adrenocortical tumors typically present during the first 5 years of life (median age, 3-4 years), although there is a second, smaller peak during adolescence. (oncolink.org)
  • Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
  • During follow-up (range, 1-13 years), 8 patients presented metastases (2 regional and 6 distant) as their first site of failure, 1 had a differed local recurrence, and 1 died of the disease. (bvsalud.org)
  • The emergence and reemergence of infectious diseases are major problems for healthcare systems worldwide. (cdc.gov)
  • We investigated frequency of, and baseline predictors of, institutionalisation in Parkinson's disease (PD). (bmj.com)
  • WCMM members Agnete Kirkeby and Gesine Paul-Visse are part of the team behind STEM-PD - a new kind of dopaminergic nerve cell therapy designed to replace cells lost in Parkinson's disease, the first of its kind in Europe! (lu.se)
  • The STEM-PD trial is investigating the safety and tolerability of transplanting STEM-PD cells into the brain of patients with moderate Parkinson's disease (EudraCT Number:2021-001366-38). (lu.se)
  • Our data shows that the STEM-PD product is safe and highly efficacious in reverting motor deficits in preclinical models of Parkinson's disease" says Agnete Kirkeby, who has led the preclinical development of the product. (lu.se)
  • Among patients on the dose dense regimens, disease-free survival was 82 percent after four years, compared to 75 percent for those who received conventional therapy. (scienceblog.com)
  • After three years, 92 percent of patients on the dose dense therapy were alive, compared to 90 percent of those on the conventionally administered regimens. (scienceblog.com)
  • Median overall survival was also superior with Keytruda in patients with a PD-L1 TPS of 50% or greater (16.9 months versus 8.2 months) and a PD-L1 TPS of 1% (11.8 months versus 8.4 months), compared with docetaxel. (curetoday.com)
  • To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). (nih.gov)
  • Researchers followed 80 previously untreated patients with a median age of 65 years, 30% of whom were over age 70. (mdanderson.org)
  • Median age was 82 years (range, 44-92). (bvsalud.org)
  • We set out to ascertain if changes in 2-year DFS can be used to accurately predict 5-year OS changes. (mcmaster.ca)
  • The PI for mutually exclusive exons had the greatest ability to predict the probability of five-year disease-free survival of patients with PRAD, with an area under the time-dependent receiver-operating characteristic curve of 0.7606. (spandidos-publications.com)
  • The five-year analysis showed an absolute difference of 1.3% (9.2% versus 7.9%), increasing to 2.6% (17.7% versus 15.1%) after 10 years ( P =0.02). (medpagetoday.com)
  • Conversely, during the rainy season, conditions at the edges of fragmented forests, where human settlements are often located, become favorable for larval habitats, rendering villagers susceptible to the disease ( 6 ). (cdc.gov)
  • Disease-free survival was 17.3 months (95% CI: 8.4-26.2) in patients with a monocyte count ≥515/μL as opposed to 38.5 months (95% CI: 28. (researchsquare.com)
  • At 12 months, nearly 74% had no signs or symptoms of the disease. (cancer.net)
  • Although pleural mesothelioma typically carries a life expectancy of just 12 to 18 months, the median overall survival for patients receiving this PD/PDT therapy combination was more than twice that at nearly three years. (survivingmesothelioma.com)
  • In these cases, the patient is followed closely with digital rectal examinations, proctoscopy, magnetic resonance imaging, and endoscopy every two or three months during the first year of follow-up. (fapesp.br)
  • The median disease-specific survival was 12.6 months in the control arm and 22.2 months in the HIPEC arm (P = 0.028). (lu.se)
  • The bimonthly sampling cycle started in January and February for 2008, and was shifted to the next 2 months every year until 2017. (who.int)
  • ary for 2008, was shifted to the next The form col ected basic personal in- · to document the disease-free 2 months every year, and restarted in formation (age, education level, mar- survival (DFS) of patients with January and February after 6 years. (who.int)
  • New research suggests that, even in patients with advanced mesothelioma, long-term survival is possible with a strategic multi-modal approach. (survivingmesothelioma.com)
  • For a selected group, there is a possibility of long-term survival. (lu.se)
  • Statement of the problem: Most of the clinical documentation of implant success and survival published in the literature have been issued by either experienced teams from university settings involving strict patient selection criteria or from seasoned private practitioners. (mdpi.com)
  • We are confident that their work will be of great benefit to other nurses, particularly those in developing countries where Hb disorders are most prevalent, and where health infrastructure and services for chronic diseases, including nursing care, are in urgent need of reinforcement and reform. (thalassaemia.org.cy)